Halozyme Therapeutics announced results from a Phase 2 study of prandial insulin formulations, which include the Company…
Insulin
Lilly’s Investigational Basal Insulin Shows Better Results than Lantus
Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal in…
Lantus Does Not Increase Cancer Risk, New Studies Show
Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the n…
Biodel Obtains Technologies for Development of Glucagon Formulations
Biodel Inc. has partnered with Aegis Therapeutics, LLC (Aegis) and has obtained exclusive worldwide license to Aegis' pr…
FDA Extends Review Period of Novo Nordisk’s Ultra-Long-Acting Insulins
The U.S. FDA has informed Novo Nordisk that a three-month extension period was required in order to complete its regulat…
Novo Nordisk’s Levemir Insulin Approved for Use in Children as Young as Two
The U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for use in ch…
Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia, New Studies Show
Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compou…
Positive Results for Biodel’s Ultra Rapid Acting Insulin
Biodel Inc. announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BI…
Using Insulin in Pregnancy: FDA Approves Levemir
Dr. Jovanovic even recommends using Levemir injections at night to women using insulin pumps, as she prefers the assuran…
FDA Approves Novo Nordisk’s Levemir Insulin for Pregnant Women with Diabetes
The U.S. FDA has approved Novo Nordisk's Levemir insulin (insulin detemir [rDNA origin] injection) for use by pregnant w…
